Literature DB >> 16476999

Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds.

Jan Pilch1, Darren M Brown, Masanobu Komatsu, Tero A H Järvinen, Meng Yang, David Peters, Robert M Hoffman, Erkki Ruoslahti.   

Abstract

Screening of a phage library for peptides that bind to clotted plasma in the presence of liquid plasma yielded two cyclic decapeptides, CGLIIQKNEC (CLT1) and CNAGESSKNC (CLT2). When injected intravenously into mice bearing various types of tumors, fluorescein-conjugated CLT peptides accumulated in a fibrillar meshwork in the extracellular compartment of the tumors, but were not detectable in other tissues of the tumor-bearing mice. The tumor homing of both peptides was strongly reduced after coinjection with unlabeled CLT2, indicating that the two peptides recognize the same binding site. The CLT peptide fluorescence colocalized with staining for fibrin(ogen) present in the extravascular compartment of tumors, but not in other tissues. The CLT peptides did not home to tumors grown in fibrinogen-null mice or in mice that lack plasma fibronectin. The CLT peptides also accumulated at the sites of injury in arteries, skeletal muscle, and skin. We conclude that the CLT peptides recognize fibrin-fibronectin complexes formed by clotting of plasma proteins that have leaked into the extravascular space in tumors and other lesions. These peptides may be useful in targeting diagnostic and therapeutic materials into tumors and injured tissues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476999      PMCID: PMC1413849          DOI: 10.1073/pnas.0511219103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Coexisting conformations of fibronectin in cell culture imaged using fluorescence resonance energy transfer.

Authors:  G Baneyx; L Baugh; V Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases.

Authors:  M Yang; E Baranov; P Jiang; F X Sun; X M Li; L Li; S Hasegawa; M Bouvet; M Al-Tuwaijri; T Chishima; H Shimada; A R Moossa; S Penman; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis.

Authors:  T Sakai; K J Johnson; M Murozono; K Sakai; M A Magnuson; T Wieloch; T Cronberg; A Isshiki; H P Erickson; R Fässler
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

4.  Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques.

Authors:  S Flacke; S Fischer; M J Scott; R J Fuhrhop; J S Allen; M McLean; P Winter; G A Sicard; P J Gaffney; S A Wickline; G M Lanza
Journal:  Circulation       Date:  2001-09-11       Impact factor: 29.690

5.  R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis.

Authors:  Masanobu Komatsu; Erkki Ruoslahti
Journal:  Nat Med       Date:  2005-11-13       Impact factor: 53.440

Review 6.  Putting tumours in context.

Authors:  M J Bissell; D Radisky
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

7.  Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.

Authors:  J S Palumbo; K W Kombrinck; A F Drew; T S Grimes; J H Kiser; J L Degen; T H Bugge
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

8.  Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.

Authors:  C Halin; S Rondini; F Nilsson; A Berndt; H Kosmehl; L Zardi; D Neri
Journal:  Nat Biotechnol       Date:  2002-03       Impact factor: 54.908

9.  Nanocrystal targeting in vivo.

Authors:  Maria E Akerman; Warren C W Chan; Pirjo Laakkonen; Sangeeta N Bhatia; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

Review 10.  Specialization of tumour vasculature.

Authors:  Erkki Ruoslahti
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

View more
  61 in total

1.  Gene delivery mediated by recombinant silk proteins containing cationic and cell binding motifs.

Authors:  Keiji Numata; Juliana Hamasaki; Balajikarthick Subramanian; David L Kaplan
Journal:  J Control Release       Date:  2010-05-10       Impact factor: 9.776

2.  MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.

Authors:  Mingqian Tan; Susan M Burden-Gulley; Wen Li; Xueming Wu; Daniel Lindner; Susann M Brady-Kalnay; Vikas Gulani; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2011-12-03       Impact factor: 4.200

Review 3.  Silk-based delivery systems of bioactive molecules.

Authors:  Keiji Numata; David L Kaplan
Journal:  Adv Drug Deliv Rev       Date:  2010-03-16       Impact factor: 15.470

Review 4.  The use of therapeutic peptides to target and to kill cancer cells.

Authors:  R J Boohaker; M W Lee; P Vishnubhotla; J M Perez; A R Khaled
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

5.  Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting.

Authors:  Ji-Ho Park; Geoffrey von Maltzahn; Lianglin Zhang; Austin M Derfus; Dmitri Simberg; Todd J Harris; Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  Small       Date:  2009-03       Impact factor: 13.281

6.  Potential of phage-displayed peptide library technology to identify functional targeting peptides.

Authors:  Lauren Rh Krumpe; Toshiyuki Mori
Journal:  Expert Opin Drug Discov       Date:  2007-04       Impact factor: 6.098

7.  Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.

Authors:  Jun Deng; Heng Mei; Wei Shi; Zhi-Qing Pang; Bo Zhang; Tao Guo; Hua-Fang Wang; Xin-Guo Jiang; Yu Hu
Journal:  Curr Med Sci       Date:  2018-06-22

Review 8.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

9.  Targeting of albumin-embedded paclitaxel nanoparticles to tumors.

Authors:  Priya Prakash Karmali; Venkata Ramana Kotamraju; Mark Kastantin; Matthew Black; Dimitris Missirlis; Matthew Tirrell; Erkki Ruoslahti
Journal:  Nanomedicine       Date:  2008-10-01       Impact factor: 5.307

Review 10.  Targeting of drugs and nanoparticles to tumors.

Authors:  Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  J Cell Biol       Date:  2010-03-15       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.